MapLight Therapeutics, Inc. (MPLT) Ownership
MPLT ownership summary
as of October 18, 2026- Institutions
- 48.8% of shares outstanding
- Insiders
- 52.28% of shares outstanding
- Shares outstanding
- 52.8M
- Float
- 16.1M shares available to trade
- Short interest
- 9.77% 3.1M shares short
- Days to cover
- 5.74 short interest down 4.5% vs prior month
- Institutions 48.80%
- Insiders 52.28%
MPLT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Novo A/S | 6.63% | 3.7M | $28.4M | — | June 30, 2026 |
| 2 | FCPM III SERVICES BV | 5.81% | 3.2M | $24.8M | — | June 30, 2026 |
| 3 | T. Rowe Price Investment Management,Inc. | 5.01% | 2.8M | $21.4M | −20,209 (−0.7%) | June 30, 2026 |
| 4 | The Goldman Sachs Group Inc | 3.51% | 1.9M | $15.0M | −46,561 (−2.3%) | June 30, 2026 |
| 5 | T. Rowe Price Associates, Inc. | 2.56% | 1.4M | $11.0M | +1.3M (+1,162.5%) | June 30, 2026 |
| 6 | BlackRock Inc | 1.84% | 1.0M | $7.9M | −314,597 (−23.5%) | June 30, 2026 |
| 7 | Nan Fung Group Holdings Ltd | 1.75% | 971K | $7.5M | — | June 30, 2026 |
| 8 | 5AM Venture Management, LLC | 1.71% | 950K | $7.3M | — | June 30, 2026 |
| 9 | Sanofi | 1.64% | 912K | $7.0M | — | June 30, 2026 |
| 10 | State Street Corp | 1.53% | 852K | $6.6M | +513,034 (+151.3%) | June 30, 2026 |
| 11 | FMR Inc | 1.48% | 824K | $6.3M | +619,055 (+302.7%) | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 1.41% | 784K | $6.0M | +64,330 (+8.9%) | June 30, 2026 |
| 13 | Blue Owl Capital Holdings LP | 1.31% | 730K | $5.6M | −276,000 (−27.4%) | June 30, 2026 |
| 14 | Paradigm Biocapital Advisors LP | 1.23% | 686K | $5.3M | +685,852 (0.0%) | June 30, 2026 |
| 15 | Pivotal bioVenture Partners Investment Advisor LLC | 1.10% | 611K | $4.7M | −1 (−0.0%) | June 30, 2026 |
| 16 | Velan Capital Investment Management LP | 0.89% | 493K | $3.8M | — | June 30, 2026 |
| 17 | Siren, L.L.C. | 0.81% | 450K | $3.5M | — | June 30, 2026 |
| 18 | Capital World Investors | 0.75% | 416K | $3.2M | +415,730 (0.0%) | June 30, 2026 |
| 19 | Geode Capital Management, LLC | 0.72% | 402K | $3.1M | −79,150 (−16.4%) | June 30, 2026 |
| 20 | Baker Bros Advisors LP | 0.66% | 365K | $2.8M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 3.6M shares and 6 cut 737K.
MPLT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 0.99% | 552K | $4.3M | — | August 31, 2026 |
| 2 | T. Rowe Price Small-Cap Value | 0.89% | 493K | $3.8M | −290 (−0.1%) | August 31, 2026 |
| 3 | T. Rowe Price Integrated US Sm Gr Eq | 0.77% | 429K | $3.3M | — | August 31, 2026 |
| 4 | Fidelity Stock Selector Small Cap | 0.73% | 406K | $3.1M | +406,402 (0.0%) | July 31, 2026 |
| 5 | American Funds SMALLCAP World A | 0.73% | 404K | $3.1M | +404,389 (0.0%) | June 30, 2026 |
| 6 | iShares Russell 2000 ETF | 0.58% | 323K | $2.5M | −3,712 (−1.1%) | September 30, 2026 |
| 7 | Fidelity Series Small Cap Opps | 0.47% | 264K | $2.0M | +263,529 (0.0%) | July 31, 2026 |
| 8 | Fidelity Advisor Biotechnology I | 0.37% | 203K | $1.6M | — | August 31, 2026 |
| 9 | MEDICAL BioHealth EUR Acc | 0.34% | 191K | $1.5M | +40 (+0.0%) | August 31, 2026 |
| 10 | AXA Framlington Health Fund - R Income | 0.31% | 171K | $1.3M | — | July 31, 2026 |
| 11 | Fidelity Series Small Cap Core | 0.25% | 138K | $1.1M | +21,700 (+18.6%) | July 31, 2026 |
| 12 | Fidelity Small Cap Index | 0.21% | 114K | $880,996 | +1,147 (+1.0%) | July 31, 2026 |
| 13 | Vanguard Explorer Inv | 0.20% | 109K | $839,054 | +108,968 (0.0%) | June 30, 2026 |
| 14 | iShares Russell 2000 Growth ETF | 0.19% | 106K | $816,431 | −134 (−0.1%) | September 30, 2026 |
| 15 | Fidelity Extended Market Index | 0.17% | 93K | $714,876 | −499 (−0.5%) | August 31, 2026 |
| 16 | Schwab US Small-Cap ETF™ | 0.16% | 91K | $700,700 | +54 (+0.1%) | September 30, 2026 |
| 17 | Fidelity Enhanced Small Cap Core ETF | 0.11% | 61K | $468,707 | +126 (+0.2%) | September 30, 2026 |
| 18 | Vanguard Russell 2000 ETF | 0.11% | 60K | $459,836 | +1,200 (+2.1%) | August 31, 2026 |
| 19 | Strategic Advisers Fidelity US TtlStk | 0.10% | 58K | $444,290 | — | August 31, 2026 |
| 20 | T. Rowe Price Integrated US SMCC Eq I | 0.10% | 57K | $440,147 | +3,613 (+6.7%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
MPLT insider transactions
latest 15| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | Robert C Malenka | Sell | $18.15 | 736 | $13,358 |
| 2026-02-23 | Robert C Malenka | Sell | $18.42 | 11,264 | $207,483 |
| 2026-02-20 | George Pavlov | Buy | $17.86 | 9,920 | $177,171 |
| 2026-02-20 | Robert C Malenka | Sell | $18.03 | 2,195 | $39,576 |
| 2026-02-19 | George Pavlov | Buy | $17.57 | 4,422 | $77,695 |
| 2026-02-18 | George Pavlov | Buy | $17.48 | 10,658 | $186,302 |
| 2026-02-13 | Robert C Malenka | Sell | $18.21 | 12,116 | $220,632 |
| 2026-02-11 | Robert C Malenka | Sell | $18.00 | 241 | $4,338 |
| 2026-02-10 | Robert C Malenka | Sell | $18.12 | 6,622 | $119,991 |
| 2026-02-10 | Timothy John Garnett | Buy | $17.89 | 14,124 | $252,678 |
| 2026-02-03 | Robert C Malenka | Sell | $18.00 | 1 | $18 |
| 2026-02-02 | Robert C Malenka | Sell | $18.02 | 7,039 | $126,843 |
| 2026-01-30 | Robert C Malenka | Sell | $18.11 | 6,612 | $119,743 |
| 2026-01-29 | Robert C Malenka | Sell | $18.55 | 21,262 | $394,410 |
| 2026-01-28 | Robert C Malenka | Sell | $18.65 | 6,524 | $121,673 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
MPLT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns MPLT
Institutional investors own 48.8% of MapLight Therapeutics's shares and insiders 52.28%. The largest holder is Novo A/S with 6.63% of the shares (3.7M), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 6 reduced their stake in the latest filings. Short interest is 9.77% of the float, or 5.74 days of average trading volume. The share count rose 6.3% since 2023.
Related: MPLT analyst forecast, MPLT key metrics. See the MPLT stock overview for the latest quote and news.
MPLT ownership FAQ
Who owns the most MapLight Therapeutics stock?
The largest shareholders of MapLight Therapeutics are Novo A/S (6.63%), FCPM III SERVICES BV (5.81%), T. Rowe Price Investment Management,Inc. (5.01%), The Goldman Sachs Group Inc (3.51%), T. Rowe Price Associates, Inc. (2.56%).
What percentage of MapLight Therapeutics is owned by institutions?
Institutions hold 48.8% of MapLight Therapeutics's shares outstanding; insiders hold 52.28%.
Which funds own MapLight Therapeutics?
The largest fund holders of MapLight Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (0.99%), T. Rowe Price Small-Cap Value (0.89%), T. Rowe Price Integrated US Sm Gr Eq (0.77%), Fidelity Stock Selector Small Cap (0.73%), American Funds SMALLCAP World A (0.73%).
What is MapLight Therapeutics's short interest?
3.1M shares of MapLight Therapeutics were sold short, 9.77% of the float; at the average daily volume it would take 5.74 days to cover.
Are insiders buying or selling MapLight Therapeutics?
Of the latest 15 reported insider transactions in MapLight Therapeutics (since January 28, 2026), 4 were purchases and 11 were sales.
How many shares of MapLight Therapeutics are outstanding?
MapLight Therapeutics has 52.8M shares outstanding, of which 16.1M are in the public float.